GlassScriptPhysician profile
John J Kalata
NPI 1104824119
$15,875.74
in general payments reported to CMS, 2019-2025
47 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,225 · 2020: $1,822 · 2021: $2,697 · 2022: $2,870 · 2023: $2,540 · 2024: $1,794 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,252 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,251.80 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,583.17 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,426.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,415.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,312.09 | 2021-2025 | |
| Novo Nordisk INC | $1,264.24 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,129.74 | 2019-2024 | Xarelto, Spravato |
| Lilly USA, LLC | $1,081.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,052.11 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Merck Sharp & Dohme LLC | $881.22 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Abbott Laboratories | $540.96 | 2020-2025 | Proclaim, Freestyle Libre 3 |
| Exact Sciences Corporation | $444.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $389.55 | 2019-2025 | Trintellix |
| Amgen INC. | $360.31 | 2019-2024 | Otezla, Repatha |
| Biohaven Pharmaceuticals, INC. | $283.87 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $274.17 | 2021-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kalata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.